15 February 2026
Genentech's Gazyva Shows Positive Phase III Results in Primary Membranous Nephropathy
Phase III study shows Gazyva achieves significant remission in primary membranous nephropathy, with safety profile consistent and no new signals. Data to be shared with health authorities.
